The Lumit™ FcRn Binding Immunoassay as a tool in the development of antibody-based therapeutics – Users share their experiences

A prolonged plasma half-life of antibody-based drugs is desirable to boost therapeutic efficacy. Their concentration within the blood is in part governed by their affinity for the neonatal Fc receptor (FcRn). Characterizing and optimizing this interaction are therefore important steps in the development process. A widely applied method, surface plasmon resonance (SPR), is time-consuming and suffers from immobilization artifacts. With the Lumit™ FcRn Binding Immunoassay, Promega has developed an effective, fast, and solution-based SPR alternative. In this webinar, you will learn about the principle of Lumit™ Immunoassays and their applications and gain valuable insights from the experience of Dr. Alwin Reiter (Formycon AG) and Dr. Louis Julien (Antibody Analytics Ltd.) on implementing the Lumit™ FcRn Binding Immunoassay for product development.